Ron Handels, William L. Herring, Sabine Grimm, Anders Sköldunger, Bengt Winblad, Anders Wimo, Linus Jönsson
{"title":"用于早期阿尔茨海默病治疗健康技术评估的新型 IPECAD 开源模型框架：开发和使用案例","authors":"Ron Handels, William L. Herring, Sabine Grimm, Anders Sköldunger, Bengt Winblad, Anders Wimo, Linus Jönsson","doi":"10.1101/2024.04.05.24305373","DOIUrl":null,"url":null,"abstract":"<strong>Objectives</strong> Market access and reimbursement decisions for new Alzheimer’s disease (AD) treatments are informed by economic evaluations. An open-source model with intuitive structure for model cross-validation can support the transparency and credibility of such evaluations. We describe the new IPECAD open-source model framework (version 2) for the health-economic evaluation of early AD treatment and use it for cross-validation and addressing uncertainty.","PeriodicalId":501072,"journal":{"name":"medRxiv - Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New IPECAD open-source model framework for the health technology assessment of early Alzheimer’s disease treatment: development and use cases\",\"authors\":\"Ron Handels, William L. Herring, Sabine Grimm, Anders Sköldunger, Bengt Winblad, Anders Wimo, Linus Jönsson\",\"doi\":\"10.1101/2024.04.05.24305373\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Objectives</strong> Market access and reimbursement decisions for new Alzheimer’s disease (AD) treatments are informed by economic evaluations. An open-source model with intuitive structure for model cross-validation can support the transparency and credibility of such evaluations. We describe the new IPECAD open-source model framework (version 2) for the health-economic evaluation of early AD treatment and use it for cross-validation and addressing uncertainty.\",\"PeriodicalId\":501072,\"journal\":{\"name\":\"medRxiv - Health Economics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Health Economics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.04.05.24305373\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Health Economics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.04.05.24305373","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目标 阿尔茨海默病（老年痴呆症）新疗法的市场准入和报销决策均以经济评估为依据。具有直观模型交叉验证结构的开源模型可提高此类评估的透明度和可信度。我们介绍了新的 IPECAD 开源模型框架（第 2 版），该框架适用于早期 AD 治疗的卫生经济评估，并可用于交叉验证和解决不确定性问题。
New IPECAD open-source model framework for the health technology assessment of early Alzheimer’s disease treatment: development and use cases
Objectives Market access and reimbursement decisions for new Alzheimer’s disease (AD) treatments are informed by economic evaluations. An open-source model with intuitive structure for model cross-validation can support the transparency and credibility of such evaluations. We describe the new IPECAD open-source model framework (version 2) for the health-economic evaluation of early AD treatment and use it for cross-validation and addressing uncertainty.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
